| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | IO102-IO103 with pembrolizumab - (basket trial) | Metastatic solid tumors | Phase 2 | Enrollment Conclusion | Intravenous | Oncology |
| Merck & Company Inc. | MK-8507-013 and Islatravir - (IMAGINE-DR) | HIV | Phase 2 | Oral | Anti-HIV | |
| Merck & Company Inc. | ALX148 and KEYTRUDA (pembrolizumab) - (ASPEN-04) | Head and Neck Squamous Cell Carcinoma | Phase 2 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | Bomedemstat and ruxolitinib | Myelofibrosis | Phase 2 | Ongoing | Oral | Hematology |
| Merck & Company Inc. | Bomedemstat | Polycythemia Vera | Phase 2 | Enrollment Initiation | Oral | Hematology |
| Merck & Company Inc. | Bomedemstat (IMG-7289) | Myelofibrosis | Phase 2 | Trial Completed | Oral | Hematology |
| Merck & Company Inc. | Tulisokibart (PRA023) - (ARTEMIS-UC) | Ulcerative colitis | Phase 2 | Data Released | Intravenous | Gastroenterology |
| Merck & Company Inc. | Ensifentrine (RPL554) | COVID-19 | Phase 2 | Trial Discontinued | Inhalation | COVID-19 |